Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7098-7104

  Gonzalez Angulo, Ana M ^a   McGuire, Sean E ^a   Buchholz, Thomas A ^a   Tucker, Susan L ^a   Kuerer, Henry M ^a   Rouzier, Roman ^a   Kau, Shu Wan ^a   Huang, Eugene H ^a   Morandi, Paolo ^a   Ocana, Alberto ^a   Cristofanilli, Massimo ^a   Valero, Vicente ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PREDNISONE; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; AGED; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PREMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 27244450479     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.124     Document Type: Review

References (30)

1. De Lena M, Zucali R, Viganotti G, et al: Combined chemotherapy- radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53-59, 1978
2. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
3. van der Hage JA, van de Velde CJH, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
4. Green M, Hortobagyi GN: Neoadjuvant chemotherapy for operable breast cancer. Oncology (Huntingt) 16:871-884:889, 2002
5. Wang J, Buchholz TA, Middleton LP, et al: Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94:3107-3114, 2002
6. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
7. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96-102, 2001
8. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046, 2002
9. Valero V, Buzdar AU, McNeese M, et al: Primary chemotherapy in the treatment of breast cancer: The University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer 2:S63-68, 2002 (suppl)
10. Singletary SE, Allred C, Ashley P, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83:803-819, 2003
11. The World Health Organization Histological Typing of Breast Tumors: Second Edition-The World Organization. Am J CNn Pathol 78:806-816, 1982
12. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
13. Kuerer HM, Newman LA, Buzdar AU, et al: Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4:230-236, 1998
14. Rahman Z, Buzdar AU, Singletary E, et al: Selection of systemic therapy: Is axillary lymph node status important? Semin Breast 1:157-166, 1998
15. Buzdar AU, Valero V, Theriault RL, et al: Pathologic complete response to chemotherapy is related with hormone receptor status. Breast Cancer Res Treat 82:S69-302a, 2003 (suppl 1)
16. Fisher ER, Sass R, Fisher B: Pathologic findings from the national surgical adjuvant breast project: Correlations with concordant and discordant estrogen and progesterone receptors. Cancer 59:1554-1559, 1987
17. Abu-Farsakh H, Sneige N, Atkinson N, et al: Tumor nuclear grade as a predictor of tumor response to preoperative chemotherapy in patients with locally advanced breast carcinoma. Mod Pathol 7:12A, 1994 (abstr 48)
18. Dabbs DJ: Ductal carcinoma of breast: Nuclear grade as a predictor of S-phase fraction. Hum Pathol 24:652-656, 1993
19. Remvikos Y, Mosseri V, Zajdela A, et al: Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 698:193-203, 1993
20. Mathieu MC, Rouzier R, Llombart-Cussac A, et al: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40:342-351, 2004
21. Gonzalez-Angulo AM, Kau SW, Broglio K, et al: Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. Proc Am Soc Clin Oncol 22:42S, 2004 (abstr 663)
22. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
23. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
24. Abrams JS: Adjuvant therapy for breast cancer: Results from the USA consensus conference. Breast Cancer 8:298-304, 2001
25. Saez RA, McGuire WL, Clark GM: Prognostic factors in breast cancer. Semin Surg Oncol 5:102-110, 1989
26. Kuerer HM, Newman LA, Buzdar AU, et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176:502-509, 1998
27. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
28. Elwood JM, Godolphin W: Oestrogen receptors in breast tumours: Associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 42:635-644, 1980
29. Thomas E, Holmes FA, Smith TL, et al: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 22:2294-2302, 2004
30. Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: A five year update of the Aberdeen trial. Breast Cancer Res Treat 82:11a, 2003 (suppl 1)